“Eight miles straight up downtown somewhere, I just dropped in to see what condition my condition was in.”

Those lyrics are from the 1968 psychedelic rock song Just Dropped In (To See What Condition My Condition Was In), by Kenny Rogers and the First Edition. A new scientific study released last week provided further scientific proof that for depressed or anxious people who ingest the psychedelic substance psilocybin, the condition of their condition is…greatly improved.

A burgeoning body of research shows that psychedelics can treat chronic mental ailments. The latest case in point: A new study, published September 19, shows that psilocybin use can cause “persisting reductions” in depression, anxiety, and alcohol abuse. Psilocybin also increases emotional self-regulation and spiritual wellbeing, and eases introversion.

Psilocybin is the psychoactive ingredient in “magic mushrooms.” Researchers at Johns Hopkins University, Ohio State University and Unlimited Sciences asserted that their research represents the “largest prospective survey of naturalistic psilocybin use to date,” providing empirical evidence that underscores the “potential for psilocybin to produce lasting improvements in mental health symptoms and general wellbeing.”

Published last week in the journal Frontiers in Psychiatry, the study encompassed 2,833 adults and administered multiple surveys before and after they used psilocybin outside of the clinical setting. Psilocybin was administered in phases between July 2020 and July 2022.

“Prospective longitudinal data collected before and after a planned psilocybin experience on average showed persisting reductions in anxiety, depression, and alcohol misuse, increased cognitive flexibility, emotion regulation, spiritual wellbeing, and extraversion, and reduced neuroticism and burnout after psilocybin use,” the authors asserted.

The most common reason that people said they took psilocybin was for “self-exploration” (81%), followed by mental health (71%), therapy (48%), creativity (44%), recreation (38%), productivity (22%), and physical health (14%).

About 22% of respondents met the criteria for having had a “complete mystical experience,” which was a “significant predictor of changes in multiple longitudinal variables including decreased depression, personal burnout, work burnout, and state anxiety, as well as increased cognitive flexibility and spiritual wellbeing.”

Prior to using psilocybin, 42% of participants met criteria for some form of depression. Symptoms of anxiety also dissipated following use of the psychedelic.

Other “commonly reported behavioral changes after psilocybin use” included improved relationships with others (50%), increased physical activity and exercise (27%), improvements in professional work (27%), and improved diet and nutrition (24%). Also, 94% of participants characterized their experience as “beneficial.”

Read This Story: Calling Dr. Freud: How Pot Is Revolutionizing Psychotherapy

Psychedelic substances are on the cusp of becoming a global, multi-billion-dollar drug business. The following infographic tells the story:

Depression is a pervasive mental health problem that afflicts millions of people worldwide. The psychedelics industry is poised to capture a significant chunk of the $28.6 billion global antidepressant market in coming years, as clinical trials increasingly show the efficacy of these substances to alleviate psychological suffering.

Meanwhile, the microdosing of psychedelics has become all the rage, especially among high-level corporate executives. The folks in the C-suites of Silicon Valley mega-caps attest to the creative, physical, and spiritual benefits of microdosing psilocybin or LSD.

Microdosing is the ingestion of tiny, sub-hallucinogenic amounts of psychedelics. Even average consumers are microdosing to relieve anxiety, release productivity, or explore their inner psyches.

Psychedelics remain prohibited on the federal level in the U.S. However, after historic legalization victories in California, Colorado, and Oregon, the campaign to expand public access to psychedelic drugs is now moving to additional states in 2023 and 2024. A statistical model recently published in the Journal of American Medicine (JAMA) predicts that most states will allow access to psychedelics over the next 10-15 years.

The time to invest in clinical stage psychedelics-focused biotech startups is now, before their share prices skyrocket and the nascent psychedelics industry goes mainstream.

Every portfolio should have exposure to companies in the cannabis and psychedelics industries. That’s why I’ve launched the trading service Marijuana Profit Alert.

MPA is your guide to reaping profits from the investment bonanza in marijuana, psilocybin, and other psychotropic drugs. Click here to learn more.

John Persinos is the editorial director of Investing Daily.

To subscribe to John’s video channel, click this icon: